Bernhard Hemmer, head of the Department of Neurology at the University Hospital of the Technical University Munich, explains: ...

When the immune system detects a harmful or foreign agent it triggers an inflammatory response small proteins called chemokines direct immune cells to the site of the injury or infection, resulting in ...

Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...

It helps align clinical practice and reimbursement pathways, ensuring that clinical decision-making and insurance coverage ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis ...

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. March is Multiple Sclerosis Awareness Month, a time to ...